Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.33 |
| ▸ | GSK3B | P49841 | 3/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | WNT1 | P04628 | 2/20 | 0.33 |
| ▸ | PTPRB | P23467 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2546671 | 0.96 | CDK2 (0.35) | DYRK1AGSK3BPDPK1WNT1PTPRB | |
| SCHEMBL1744914 | 0.94 | DYRK1A (0.33) | DYRK1AGSK3BPDPK1WNT1PTPRB | |
| SCHEMBL12241700 | 0.93 | DYRK1A (0.35) | DYRK1AGSK3BPDPK1WNT1 | |
| SCHEMBL1744751 | 0.90 | CDK2 (0.35) | DYRK1AGSK3BPDPK1WNT1PTPRB | |
| SCHEMBL2550224 | 0.89 | PDPK1 (0.33) | DYRK1AGSK3BPDPK1WNT1 | |
| SCHEMBL1743833 | 0.85 | PDPK1 (0.33) | DYRK1AGSK3BPDPK1WNT1CDK2 | |
| SCHEMBL1742991 | 0.84 | AAK1 (0.31) | DYRK1AGSK3B | |
| SCHEMBL1744755 | 0.83 | GSK3B (0.31) | DYRK1AGSK3BPDPK1WNT1PTPRB | |
| SCHEMBL1743840 | 0.82 | AKT1 (0.40) | DYRK1AGSK3BPDPK1WNT1PTPRB | |
| SCHEMBL12241701 | 0.82 | DYRK1A (0.33) | DYRK1AGSK3BPDPK1WNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387570-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2010083246-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | DYRK1A 2916/4885GSK3B 145/4885PDPK1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.